Unmet needs: Research helps regulators do their jobs

Science Translational Medicine

Volumn 7, Issue 315, 2015, Pages

  Altman, Russ B ^a   Khuri, Natalia ^a,b   Salit, Marc ^a,c   Giacomini, Kathleen M ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NANOMATERIAL;

BEHAVIORAL SCIENCE; BIOINFORMATICS; CELL THERAPY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; KNOWLEDGE BASE; MEDICAL DEVICE REGULATION; MEDICAL DOCUMENTATION; NEXT GENERATION SEQUENCING; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGULATORY SCIENCE RESEARCH; RESEARCH; REVIEW; SOCIOLOGY; SPINE IMPLANT; STANDARDIZATION; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DEVICES; HEALTH SERVICE; UNITED STATES;

CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EQUIPMENT AND SUPPLIES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; NANOSTRUCTURES; RESEARCH; UNITED STATES;

EID: 84954408826     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac4369     Document Type: Review

References (49)

1. FDA science board, "FDA science and mission at risk" (2007); available at http://iom.nationalacademies.org/~/media/Files/Activity%20Files/PublicHealth/MedPrep/2010-FEB-22/Feb-24-Session-5-Cassell-FDA-Science.pdf.
2. FDA, "Advancing regulatory science at FDA" (2011); available at www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/UCM268225.pdf.
3. FDA, "Centers of Excellence in Regulatory Science and Innovation" (2015); available at www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm301667.htm.
4. J. Woodcock, "CDER Priorities" (2014); available at www.fda.gov/downloads/AboutFDA/CentersOf ces/Of ceof-MedicalProductsandTobacco/CDER/UCM426673.pdf.
5. FDA Center for Tobacco Products, "Center for Tobacco Products Research Priorities" (2014); available at www.fda.gov/downloads/TobaccoProducts/NewsEvents/UCM382852.pdf.
6. FDA Center for Devices and Radiological Health, "CDRH Strategic Priorities and Updates" (2014); available at www.fda.gov/AboutFDA/CentersOf ces/Of ceofMedicalProductsandTobacco/CDRH/CDRHVisionandMission/default.htm.
7. FDA Center for Biologics Evaluation and Research, "Innovative Technology Advancing Public Health" (2011); available at www.fda.gov/downloads/aboutfda/centersof ces/cber/ucm266867.pdf.
8. FDA, Assessing the Center of Drug Evaluation and Research's safety-related regulatory science needs and identifying priorities. Fed. Regist. 80, 14389-14390 (2015).
9. FDA, Pilot program for qualif cation of medical device development tools. Fed. Regist. 79, 48170-48172 (2014).
10. FDA, Next generation sequencing diagnostic tests; Public workshop; Request for comments. Fed. Regist. 79, 78092-78093 (2014).
11. FDA, "FDA's Sentinel initiative" (2008); available at www.fda.gov/Safety/FDAsSentinelInitiative/ucm2007250.htm.
12. FDA, "FDA Adverse Event Reporting System (FAERS) " (2014); available at www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/Adverse-DrugEf ects/default.htm.
13. U. S. Centers for Disease Control and Prevention and FDA, "Vaccine Adverse Event Reporting System (VAERS) " (2015); available at https://vaers.hhs.gov/index.
14. FDA, "MAUDE-Manufacturer and User Facility Device Experience" (2015); available at www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfmaude/search.cfm.
15. L. G. Biesecker, R. C. Green, Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 370, 2418-2425 (2014).
16. T. Shen, S. H. Pajaro-Van De Stadt, N. C. Yeat, J. C. Lin, Clinical applications of next generation sequencing in cancer: From panels, to exomes, to genomes. Front. Genet. 6, 215 (2015).
17. R. Simon, S. Roychowdhury, Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 12, 358-369 (2013).
18. D. A. Relman, Microbial genomics and infectious diseases. N. Engl. J. Med. 365, 347-357 (2011).
19. M. E. Norton, B. Jacobsson, G. K. Swamy, L. C. Laurent, A. C. Ranzini, H. Brar, M. W. Tomlinson, L. Pereira, J. L. Spitz, D. Hollemon, H. Cuckle, T. J. Musci, R. J. Wapner, Cell-free DNA analysis for noninvasive examination of trisomy. N. Engl. J. Med. 372, 1589-1597 (2015).
20. H. L. Rehm, S. J. Bale, P. Bayrak-Toydemir, J. S. Berg, K. K. Brown, J. L. Deignan, M. J. Friez, B. H. Funke, M. R. Hegde, E. Lyon, Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee, ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15, 733-747 (2013).
21. FDA, "Optimizing FDA's regulatory oversight of next generation sequencing diagnostic tests-Preliminary discussion paper" (2015); available at www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM427869.pdf.
22. H. L. Rehm, J. S. Berg, L. D. Brooks, C. D. Bustamante, J. P. Evans, M. J. Landrum, D. H. Ledbetter, D. R. Maglott, C. L. Martin, R. L. Nussbaum, S. E. Plon, E. M. Ramos, S. T. Sherry, M. S. Watson, ClinGen-The clinical genome resource. N. Engl. J. Med. 372, 2235-2242 (2015).
23. FDA, "Factors to consider when making benef t-risk determinations in medical device premarket approval and de novo classif cations" (2012). www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM296379.pdf.
24. M. P. Ho, J. M. Gonzalez, H. P. Lerner, C. Y. Neuland, J. M. Whang, M. McMurry-Heath, A. Brett Hauber, T. Irony, Incorporating patient-preference evidence into regulatory decision making. Surg. Endosc. 29, 2984-2993 (2015).
25. C. A. Roberto, N. Khandpur, Improving the design of nutrition labels to promote healthier food choices and reasonable portion sizes. Int. J. Obesity (London) 38(suppl. 1), S25-S33 (2014).
26. C. J. Choniniere, A. Lando, "2008 health and diet survey: Topline frequency report" (2008); available at http://www.fda.gov/Food/FoodScienceResearch/Consumer-BehaviorResearch/ucm193895.htm.
27. FDA, "Food labeling guide" (1994); available at www.fda. gov/Food/GuidanceRegulation/GuidanceDocuments-RegulatoryInformation/LabelingNutrition/ucm2006828.htm.
28. D. Kok, M. Grevitt, F. Wapstra, A. Veldhuizen, The memory metal spinal system in a posterior lumbar interbody fusion (PLIF) procedure: A prospective, non-comparative study to evaluate the safety and performance. Open Orthop. J. 6, 220-225 (2012).
29. C. Oksel, C. Y. Ma, X. Z. Wang, Current situation on the availability of nanostructure-biological activity data. SAR QSAR Environ. Res. 26, 79-94 (2015).
30. R. Tantra, C. Oksel, T. Puzyn, J. Wang, K. N. Robinson, X. Z. Wang, C. Y. Ma, T. Wilkins, Nano (Q) SAR: Challenges, pitfalls and perspectives. Nanotoxicology 9, 636-642 (2015).
31. D. A. Winkler, E. Mombelli, A. Pietroiusti, L. Tran, A. Worth, B. Fadeel, M. J. McCall, Applying quantitative structureactivity relationship approaches to nanotoxicology: Current status and future potential. Toxicology 313, 15-23 (2013).
32. L. X. Yu, W. Jiang, X. Zhang, R. Lionberger, F. Makhlouf, D. J. Schuirmann, L. Muldowney, M. L. Chen, B. Davit, D. Conner, J. Woodcock, Novel bioequivalence approach for narrow therapeutic index drugs. Clin. Pharmacol. Ther. 97, 286-291 (2015).
33. U. S. Food and Drug Administration, Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing; Request for Comments. Fed. Regist. 78, 27113-27115 (2013).
34. U. S. Food and Drug Administration, "Adaptive design clinical trials for drugs and biologics" (2010); available at www.fda.gov/downloads/Drugs/.../Guidances/ucm201790.pdf.
35. L. Pregelj, M. L. Verreynne, D. Hine, Changes in clinical trial length. Nat. Rev. Drug Discov. 14, 307-308 (2015).
36. U. S. Food and Drug Administration, "Electronic source data in clinical investigations" (2013); available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM328691.pdf.
37. R. M. Samsonraj, B. Rai, P. Sathiyanathan, K. J. Puan, O. Rötzschke, J. H. Hui, M. Raghunath, L. W. Stanton, V. Nurcombe, S. M. Cool, Establishing criteria for human mesenchymal stem cell potency. Stem Cells 33, 1878-1891 (2015).
38. J. Ankrum, J. M. Karp, Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol. Med. 16, 203-209 (2010).
39. A. French, C. Bravery, J. Smith, A. Chandra, P. Archibald, J. D. Gold, N. Artzi, H. W. Kim, R. W. Barker, A. Meissner, J. C. Wu, J. C. Knowles, D. Williams, G. García-Cardeña, D. Sipp, S. Oh, J. F. Loring, M. S. Rao, B. Reeve, I. Wall, A. J. Carr, K. Bure, G. Stacey, J. M. Karp, E. Y. Snyder, D. A. Brindley, Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards. Stem Cells Transl. Med. 4, 217-223 (2015).
40. M. Mendicino, A. M. Bailey, K. Wonnacott, R. K. Puri, S. R. Bauer, MSC-based product characterization for clinical trials: An FDA perspec tive. Cell Stem Cell 14, 141-145 (2014).
41. J. Lo Surdo, S. R. Bauer, Quantitative approaches to detect donor and passage dif erences in adipogenic potential and clonogenicity in human bone marrow-derived mesenchymal stem cells. Tissue Eng. Part C Methods 18, 877-889 (2012).
42. J. L. Lo Surdo, B. A. Millis, S. R. Bauer, Automated microscopy as a quantitative method to measure dif erences in adipogenic dif erentiation in preparations of human mesenchymal stromal cells. Cytotherapy 15, 1527-1540 (2013).
43. I. H. Bellayr, J. G. Catalano, S. Lababidi, A. X. Yang, J. L. Lo Surdo, S. R. Bauer, R. K. Puri, Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Res. Ther. 5, 59 (2014).
44. P. J. Lynch, E. E. Thompson, K. McGinnis, Y. I. Rovira Gonzalez, J. Lo Surdo, S. R. Bauer, D. A. Hursh, Chromatin changes at the PPAR-γ2 promoter during bone marrowderived multipotent stromal cell culture correlate with loss of gene activation potential. Stem Cells 33, 2169-2181 (2015).
45. C. Nazarov, J. Lo Surdo, S. R. Bauer, C. H. Wei, Assessment of immunosuppressive activity of human mesenchymal stem cells using murine antigen specif c CD4 and CD8 T cells in vitro. Stem Cell Res. Ther. 4, 128 (2013).
46. S. T. Mindaye, M. Ra, J. Lo Surdo, S. R. Bauer, M. A. Alterman, Improved proteomic prof ling of the cell surface of culture-expanded human bone marrow multipotent stromal cells. J. Proteomics 78, 1-14 (2013).
47. S. T. Mindaye, M. Ra, J. L. Lo Surdo, S. R. Bauer, M. A. Alterman, Global proteomic signature of undif erentiated human bone marrow stromal cells: Evidence for donorto-donor proteome heterogeneity. Stem Cell Res. (Amst.) 11, 793-805 (2013).
48. P. W. Andrews, J. Cavagnaro, R. Deans, E. Feigal, E. Horowitz, A. Keating, M. Rao, M. Turner, I. Wilmut, S. Yamanaka, Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nat. Biotechnol. 32, 724-726 (2014).
49. E. Dolgin, Better standards sought for range of stem cells entering the clinic. Nat. Med. 20, 797-798 (2014).